|
Scientists have published two studies describing how genetically
modified bacteria could help detect cancerous tumours and diabetes in mice, and
potentially be used as a diagnostic tool for humans.
The first study, which was published
in the journal Science Translational Medicine, revelled how scientists had
modified E. coli bacteria and transformed it into a sort of living sensor,
which could stay in a mouse’s body for up to a month and detect tumours inside
its body.
RT.com reports:
Typically E. coli is able to pass
through the gut walls and colonize liver tumours, but scientists modified the
bacteria to produce an enzyme which changes the colour of a mouse’s urine, as
an early warning system. Although in mice the genetically modified E. coli
showed visible evidence of cancerous tumour presence within 24 hours, the
method will have to be proven to work in humans, whose gut microbiomes are very
different from those in mice.
In the second study
researchers used the bacteria to look for glycosuria in humans, the presence of
sugar in urine, which is a sure sign of uncontrolled diabetes. The E. coli
bacteria turned urine red in 89 percent of cases where glycosuria was present
and suggested diabetes was present when in fact it was not in just 3 percent of
cases.
The study’s researchers are working
on liver cancer at the Massachusetts Institute of Technology and UC San Diego,
and diabetes at University of Montpellier in France and Stanford University.
They say their works are crucially important in improving the diagnosis and
treatment of diseases, which can go undetected for some time.
The new studies “elegantly merge the promise of
synthetic biology with very practical and clinical applications in biosensors,”
director of the National Institute of Biomedical Imaging and Bioengineering's
program in synthetic biology for technology development, Jessica Tucker, told
the LA Times. The bacteria “sensors” could one day allow doctors in remote
clinics to easily diagnose and then monitor the treatment of a number of
diseases.
No comments:
Post a Comment